Skip to Main Content

The Australian consumer watchdog agency is taking Novartis (NVS) and GlaxoSmithKline (GSK) to court for allegedly false or misleading marketing about a pair of gels used to treat pain.

The move is the latest by the Australian Competition and Consumer Commission to crack down on drug makers for making “misleading representations” about their products. Last year, the agency fined Reckitt Benckiser $4.5 million for deceptive practices in promoting a pain medication.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.